Our portfolio company, Encycle Therapeutics, has been acquired by Danish Zealand Pharma. The transaction strengthens the leadership of Zealand Pharma (NASDAQ: ZEAL) in peptide therapeutics and in targeting gastrointestinal diseases with the addition of a pre-clinical, orally-delivered macrocycle peptide (integrin alpha-4-beta-7 inhibitor). Encycle is founded on research coming from University of Toronto - a TIAP member institution. Read more here: http://bit.ly/2W2hH4N
TORONTO, November 1, 2017 – Encycle Therapeutics (“Encycle”), a Toronto-based drug discovery company built on a unique chemistry that enables the synthesis of a new type of constrained peptide called “nacellins,” today announced a research collaboration with Pfizer Inc. (“Pfizer”) (NYSE: PFE).
Encycle and Pfizer will partner to optimize certain nacellins, which were previously identified by Pfizer during a screening of Encycle’s proprietary nacellin library, that act on an undisclosed therapeutic target.
Nacellins are a type of peptide macrocycle that can often exhibit ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published the following guest column by Dr. Raphael Hofstein, MaRS Innovation’s president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
There’s a historical trend in Canadian culture with far-reaching effects for the way we do business, ranging from entertainment to academia to science. Namely, it’s that until quite recently, Canadians weren’t into cultivating national star systems. 
As Gideon Hayden recently wrote for TechCrunch, if you’re a Canadian tall poppy ...
2015 created a flurry of activity for MaRS Innovation and our portfolio. As the holidays begin, here are our picks for the top 10 news stories from MI's portfolio in 2015. We look forward to more exciting developments in 2016.
You may also have noticed we've refreshed our website and re-organized how we communicate about our work and services. We'd love to hear your thoughts: contact Elizabeth Monier-Williams.
Top 10 MI Portfolio Stories for 2015
1. ChipCare Corporation, a University of Toronto start-up company ...
TORONTO, ON (September 30, 2015) — Encycle Therapeutics, Inc., a University of Toronto spin-off company created in partnership with MaRS Innovation, announced today that it has completed a $2.85 million (CAD) financing led by Takeda Pharmaceutical Company Ltd. through its venture capital arm, Takeda Ventures, Inc., with Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund.
This news was covered in PEHub, BetaKit and TechVibes.
The funding will support ongoing development of Encycle’s unique nacellin platform chemistry and advance the company’s ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation's president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals:
The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office ...
MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses.
Here are our picks for the top 10 news stories from MaRS Innovation's portfolio.
1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study ...
"The first disclosed grant under Merck & Co. Inc.'s Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin [a4b7,] inhibitors for inflammatory bowel disease," writes Michael J. Haas in SciBX's feature on the partnership, "Merck Encycles through Canada." The article appears in the publication's December 4, 2014 issue.
Read the Encycle press release that prompted this article.
The article explores the current grant partnership between Merck, Encycle Therapeutics, MaRS Innovation, the Institute for ...